RF Lung Ablation Associated With Deaths, FDA Says
This article was originally published in The Gray Sheet
Executive Summary
A Dec. 11 FDA health notice links several patient deaths to radiofrequency ablation of lung tumors and notes that the uses were off-label
You may also be interested in...
Lung Tumor RF Ablation Trials Should Assess Survival Benefit – FDA Panel
Survival rates following lung tumor treatment with RITA Medical Systems' StarBurst radiofrequency (RF) ablation device should be assessed at one year, FDA's General & Plastic Surgery Devices Panel recommends
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.